PF 07293893
Alternative Names: PF-07293893Latest Information Update: 19 Jul 2024
At a glance
- Originator Pfizer
- Class Heart failure therapies
- Mechanism of Action AMP activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Heart failure
Most Recent Events
- 23 May 2024 Pfizer initiates a phase I clinical trial in Heart failure (In volunteers) in USA (PO) (NCT06413693)
- 16 May 2024 Pfizer plans a phase I trial (In volunteers) (PO) in May 2024 (NCT06413693)
- 20 Dec 2023 Phase-I clinical trials in Heart failure (In volunteers) in Belgium (PO) (NCT06177457)